Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Explains Plans To Speed Up Variant Vaccine Approvals

New EMA Expert Group Will Probe AZ Vaccine Blood Clot Issue

Executive Summary

The EU institutions are taking steps to preserve the effectiveness of existing vaccines in the face of mutations in the SARS-CoV-2 virus.

You may also be interested in...



EU Launches Faster Process For Approving Variant Vaccines

Amid the growing threat posed by variants of the coronavirus, the European Commission has published new rules allowing modified vaccines to be approved more quickly. The UK has identified one version of the B.1.167 virus variant as the most transmissible, although the jury is still out on its ability to evade vaccine protection.

EU Reveals Plan To Speed Development Of New COVID-19 Therapies

Regulatory flexibilities such as rolling review, conditional marketing authorizations and possibly an EU emergency use authorization will play a key part in the EU’s plans to identify and approve promising new coronavirus treatments.

France To Replace AstraZeneca Booster With mRNA Jab In Under-55s

The French authorities believe that the “heterologous prime-boost” approach is justified in the case of people aged under 55 years who are due to receive their second dose of the AZ COVID-19 vaccine.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel